Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors

N. Fazio, JF. Martini, AE. Croitoru, M. Schenker, S. Li, B. Rosbrook, K. Fernandez, J. Tomasek, E. Thiis-Evensen, M. Kulke, E. Raymond,

. 2019 ; 15 (17) : 1997-2007. [pub] 20190514

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze IV, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006367
E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2005-02-01 do 2020-12-31
Health & Medicine (ProQuest) od 2005-02-01 do 2020-12-31

Odkazy

PubMed 31084373
DOI 10.2217/fon-2018-0934
Knihovny.cz E-zdroje

Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion:IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006367
003      
CZ-PrNML
005      
20200526110250.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2018-0934 $2 doi
035    __
$a (PubMed)31084373
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Fazio, Nicola $u Division of Gastrointestinal Medical Oncology & Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
245    10
$a Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors / $c N. Fazio, JF. Martini, AE. Croitoru, M. Schenker, S. Li, B. Rosbrook, K. Fernandez, J. Tomasek, E. Thiis-Evensen, M. Kulke, E. Raymond,
520    9_
$a Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan-Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher's exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion:IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-1beta $x genetika $7 D053583
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neuroendokrinní nádory $x farmakoterapie $x genetika $x mortalita $7 D018358
650    _2
$a nádory slinivky břišní $x farmakoterapie $x genetika $x mortalita $7 D010190
650    _2
$a farmakogenomické testování $7 D000071185
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $x škodlivé účinky $7 D047428
650    _2
$a sunitinib $x aplikace a dávkování $x škodlivé účinky $7 D000077210
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
700    1_
$a Martini, Jean-Francois $u Pfizer Inc, La Jolla, CA, USA.
700    1_
$a Croitoru, Adina E $u Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania.
700    1_
$a Schenker, Michael $u Centrul de Oncologie Sf. Nectarie, Oncologie Medicala, Craiova, Romania.
700    1_
$a Li, Sherry $u Pfizer Inc, La Jolla, CA, USA.
700    1_
$a Rosbrook, Brad $u Pfizer Inc, La Jolla, CA, USA.
700    1_
$a Fernandez, Kathrine $u Pfizer Inc, Cambridge, MA, USA.
700    1_
$a Tomasek, Jiri $u Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
700    1_
$a Thiis-Evensen, Espen $u Department of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
700    1_
$a Kulke, Matthew $u Boston University & Boston Medical Center, Boston, MA, USA.
700    1_
$a Raymond, Eric $u Department of Medical Oncology, Paris Saint-Joseph Hospital Group, Paris, France.
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 15, č. 17 (2019), s. 1997-2007
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31084373 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526110246 $b ABA008
999    __
$a ok $b bmc $g 1525225 $s 1096423
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 15 $c 17 $d 1997-2007 $e 20190514 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace